Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
Rhea-AI Summary
Dianthus Therapeutics (Nasdaq: DNTH) has announced its participation in three major healthcare investor conferences. CEO Marino Garcia will present corporate overviews at the Guggenheim Healthcare Innovation Conference (November 11, 1:30 p.m. ET, Boston), Jefferies Global Healthcare Conference (November 19, 9:00 a.m. GMT, London), and 7th Annual Evercore HealthCONx Conference (December 4, 10:50 a.m. ET, Coral Gables). Live webcasts will be available on the company's website under the Investors section.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, DNTH gained 0.96%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024:
- Guggenheim Healthcare Innovation Conference on November 11 at 1:30 p.m. ET in Boston, MA
- Jefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London
- 7th Annual Evercore HealthCONx Conference on December 4 at 10:50 a.m. ET in Coral Gables, FL
Live webcasts of the Company’s presentations at these three conferences may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
FAQ
When is Dianthus Therapeutics (DNTH) presenting at the Guggenheim Healthcare Conference in 2024?
What investor conferences is Dianthus Therapeutics (DNTH) attending in November-December 2024?
Where can investors watch Dianthus Therapeutics (DNTH) conference presentations?
